AI summary · may contain errors
Once-weekly subcutaneous semaglutide in children aged 6 to <12 years with obesity reduced mean BMI by -13.5% at week 68 versus 2.7% with placebo.
- 1 on Bluesky
Moving in New England Journal of Medicine.
Rebuilt
AI summary · may contain errors
Once-weekly subcutaneous semaglutide in children aged 6 to <12 years with obesity reduced mean BMI by -13.5% at week 68 versus 2.7% with placebo.
Newest first · last 60 days
AI summary · may contain errors
In US children, obesity affects 15% of ages 2–5 and 22% of ages 6–11, and is linked to dyslipidemia, hypertension, steatotic liver disease, and obstructive sleep apnea.
AI summary · may contain errors
Compounded GLP-1 weight-loss prescriptions show distinct dispensing patterns, including self-payment rates, out-of-state dispensing, and specific ingredient coformulations identified from prescription monitoring data.
AI summary · may contain errors
Once-weekly tirzepatide plus healthy lifestyle intervention in adolescents aged 12 to <18 with obesity or overweight and complications reduced BMI by 18.5% at week 72 versus 0.5% with placebo.
AI summary · may contain errors
Once-weekly subcutaneous ribupatide in adults in China with overweight or obesity without diabetes produced greater week-48 weight loss than placebo, reaching -17.7% with 6 mg.
AI summary · may contain errors
In adults with overweight or obesity without diabetes in REDEFINE 9, once-weekly cagrilintide-semaglutide 1·7 mg each and 1·0 mg each reduced bodyweight by about 20% at week 68 versus about 2% with placebo.
AI summary · may contain errors
A mathematical model jointly describing mouse appetite-driven meal intake across diets and GLP-1RA treatments (semaglutide, exenatide) passed qualitative checks and a chi2 test with disagreement below threshold (348<1111).
AI summary · may contain errors
Retatrutide 12 mg delivered the largest placebo-adjusted 52-week weight reduction in adults with overweight or obesity, at -19.80 percentage points (95% CrI -21.81 to -17.78).
AI summary · may contain errors
Rare damaging GLP1R variants in 13,725 GLP-1RA–treated adults are linked to less weight loss with semaglutide, while tirzepatide weight loss remains near-normal in carriers.
AI summary · may contain errors
Adding thrice-weekly resistance exercise to tirzepatide in 120 adults with overweight or obesity attenuated total lean soft tissue loss by 1.09 kg over 40 weeks.
AI summary · may contain errors
In adults with obesity, once-weekly retatrutide produced greater weight loss than placebo over 80 weeks, reaching -25.0% with 12 mg versus -3.9%.
AI summary · may contain errors
NNC0130, an orally available GLP-1R/GIPR dual agonist, produced placebo-corrected mean body weight loss of 9% after 12 weeks and 12% after 15 weeks with daily subcutaneous dosing.
AI summary · may contain errors
Once-weekly petrelintide in adults without type 2 diabetes produced a mean bodyweight reduction of -7·9% to -9·4% at 28 weeks versus -1·7% with placebo.
AI summary · may contain errors
In England, initiation of oral second-generation antipsychotics in adults with severe mental illness is linked to a rapid HbA1c rise of 0·12 mmol/mol per week during the first 90 days.
AI summary · may contain errors
Large-scale randomized evidence shows weight loss from incretin-based therapies is a disease-modifying strategy in several obesity-related conditions, with average weight loss of about 14–20% in people without diabetes.
AI summary · may contain errors
In a cohort of youths aged 12–21 years with overweight or obesity, glucagon-like peptide-1 receptor agonist therapy is explored for its association with biliary outcomes.
AI summary · may contain errors
In diet-induced obese male rats, chronic semaglutide treatment improves sperm motility and mucus penetration and attenuates weight-loss–linked reductions in all androgens measured after 4 weeks.
AI summary · may contain errors
In 483 adults with obesity, a dc-GE/GLP-1 subphenotype (n = 130; 26.9%) shows fast gastric emptying with discordantly low postprandial GLP-1 and reduced mucosal GCG expression.
AI summary · may contain errors
In a UK observational cohort of 8,127 women starting GLP-1RA therapy (99.8% tirzepatide) via a digital program, mean weight fell 16.1 kg over follow-up.
AI summary · may contain errors
Semaglutide 2.4 mg weekly in adults with cardiovascular disease and BMI ≥27 shows consistent hazard ratios for the primary cardiovascular composite across frailty categories.
AI summary · may contain errors
Once-weekly subcutaneous mazdutide in US adults with obesity or overweight produced least-squares bodyweight reductions at 32 weeks, reaching -18·1% with 16 mg versus -0·9% with placebo.
Journals this month
Topics moving, week to 18 Nov 2026
By field